

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code	BDA
Shares on issue	105.8m
Market Capitalisation	~\$41.3m

BOARD & MANAGEMENT

Mr Mark Masterson
Non-Executive Chairman

Ms Jo Patterson
Chief Executive Officer

Mr Akash Bedi
Non-Executive Director

Mr George Livery
Non-Executive Director

Mr Patrice Malard
Non-Executive Director

Mr Simon O'Loughlin
Non-Executive Director

Mr Stephen Kelly
Company Secretary

CONTACT

Level 1, 377 New South Head Rd
Double Bay, NSW 2028

T +612 9199 5018
E info@bodaustralia.com.au

Results of Annual General Meeting

Sydney, Australia – 4 June 2021: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA or the "Company") announces the results of the Company's Extraordinary General Meeting of shareholders that was held today.

Voting on the resolutions put to the meeting was conducted via poll and the results of the poll are reflected in the attached annexure, along with details of valid proxies received prior to the meeting.

All three resolutions put to the meeting were approved by the required majority.

This release was authorised by Stephen Kelly, Company Secretary of Bod Australia Limited

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven, and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research, and trials.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

BOD AUSTRALIA LIMITED

RESULTS OF EXTRAORDINARY GENERAL MEETING Friday, 4 June 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting		Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting)			
No	Short Description	For	Against	Discretionary (open votes)	Abstain or excluded**	For	Against	Abstain or excluded **	Result
1	RATIFICATION OF PLACEMENT SHARES UNDER LISTING RULE 7.1 (<i>Ordinary Resolution</i>)	32,808,943 98.89%	146,494 0.44%	220,233 0.66%	15,237,524	33,069,176 99.02%	146,494 0.44%	15,237,524	Carried
2	RATIFICATION OF PLACEMENT SHARES UNDER LISTING RULE 7.1A (<i>Ordinary Resolution</i>)	32,781,782 98.81%	173,293 0.52%	220,233 0.66%	15,237,024	33,042,015 99.47%	173,923 0.53%	15,237,524	Carried
3	CHANGE OF NAME TO BOD LIMITED (<i>Special Resolution</i>)	43,028,834 99.26%	27,094 0.06%	292,733 0.68%	5,064,171	43,361,567 99.94%	27,094 0.06%	5,064,171	Carried

** - Note that votes relating to a person who abstains from, or who is excluded from voting on, a resolution are not counted in determining whether or not the required majority of votes were cast for or against that resolution